1. Academic Validation
  2. Novel PROTAC probes targeting KDM3 degradation to eliminate colorectal cancer stem cells through inhibition of Wnt/β-catenin signaling

Novel PROTAC probes targeting KDM3 degradation to eliminate colorectal cancer stem cells through inhibition of Wnt/β-catenin signaling

  • RSC Med Chem. 2024 Sep 13. doi: 10.1039/d4md00122b.
Shadid U Zaman 1 Piyusha P Pagare 1 Hongguang Ma 1 Rosalie G Hoyle 1 Yan Zhang 1 Jiong Li 1 2 3
Affiliations

Affiliations

  • 1 Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University Richmond Virginia 23298-0540 USA yzhang2@vcu.edu jli29@vcu.edu.
  • 2 Department of Oral and Craniofacial Molecular Biology, Virginia Commonwealth University Richmond Virginia 23298-0540 USA.
  • 3 Massey Cancer Center, Virginia Commonwealth University Richmond Virginia 23298-0540 USA.
Abstract

It has been demonstrated that the KDM3 family of histone demethylases (KDM3A and KDM3B) epigenetically control the functional properties of colorectal Cancer Stem Cells (CSCs) through Wnt/β-catenin signaling. Meanwhile, a broad-spectrum Histone Demethylase Inhibitor, IOX1, suppresses Wnt-induced colorectal tumorigenesis predominantly through inhibiting the enzymatic activity of KDM3. In this work, several Cereblon (CRBN)-recruiting PROTACs with various linker lengths were designed and synthesized using IOX1 as a warhead to target KDM3 proteins for degradation. Two of the synthesized PROTACs demonstrated favorable degradation profile and selectivity towards KDM3A and KDM3B. Compound 4 demonstrated favorable in vitro metabolic profile in liver Enzymes as well as no hERG-associated cardiotoxicity. Compound 4 also showed dramatic ability in suppressing oncogenic Wnt signaling to eliminate colorectal CSCs and inhibit tumor growth, with around 10- to 35-fold increased potency over IOX1. In summary, this study suggests that PROTACs provide a unique molecular tool for the development of novel small molecules from the IOX1 skeleton for selective degradation of KDM3 to eliminate colorectal CSCs via suppressing oncogenic Wnt signaling.

Figures
Products
Inhibitors & Agonists
Other Products